1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses.

ABSTRACT:

Objective

Actinic keratoses (AKs) are cutaneous lesions that arise in sun-damaged skin. AKs may transform into squamous cell carcinoma in situ. Tirbanibulin 1% ointment is a new topical treatment for AKs, recently approved by the Food and Drug Administration.

Data sources

The PubMed database was searched for articles published from 1960 to March 31, 2021, using the keywords tirbanibulin and Klisyri.

Data extraction

Phase 2 and phase 3 clinical trials were reviewed.

Data synthesis

In phase 2 clinical trials, 43% of patients treated with tirbanibulin experienced complete clearance by day 57 (43% [95% CI = 32, 54]). Across two phase 3 clinical trials (pooled data), complete (100%) clearance occurred in 49% of patients in tirbanibulin groups and in on

SUBMITTER: Dao DD 

PROVIDER: S-EPMC8899810 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature